• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JSPR alert in real time by email
    SC 13G/A 1 d11530244_13g-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Jasper Therapeutics, Inc.
    (Name of Issuer)

     

     

    Voting Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

     

    471871202
    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     
     

     

    CUSIP No. 471871202    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     
     
     

     

    CUSIP No. 471871202    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     
     
     

     

    CUSIP No. 471871202    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners Fund (GP) LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     
     
     

     

    CUSIP No. 471871202    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     
     
     

     

    CUSIP No. 471871202    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Master Fund LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     
     
     

     

    CUSIP No. 471871202    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      David Witzke  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     
     
     

     

    CUSIP No. 471871202    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Michael Gregory  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      0  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     
     

     

     

     

    Item 1. (a). Name of Issuer:  
           
        Jasper Therapeutics, Inc.  

     

      (b). Address of issuer's principal executive offices:  
           
       

    2200 Bridge Pkwy, Suite #102

    Redwood City, California 94065

     

     

    Item 2. (a). Name of person filing:  
           
       

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

    David Witzke

    Michael Gregory

     

     

      (b). Address or principal business office or, if none, residence:  
           
       

    Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Partners Management (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners Fund (GP) LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Master Fund LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    David Witzke

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Michael Gregory

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

     

     

     

     
     

     

     

     

      (c). Citizenship:  
           
       

    Avidity Partners Management LP – Delaware

    Avidity Partners Management (GP) LLC – Delaware

    Avidity Capital Partners Fund (GP) LP – Delaware

    Avidity Capital Partners (GP) LLC – Delaware

    Avidity Master Fund LP – Cayman Islands

    David Witzke – United States of America

    Michael Gregory – United States of America

     

     

      (d).   Title of class of securities:  
           
        Voting Common Stock, par value $0.0001 per share  

     

      (e). CUSIP No.:  
           
        471871202  

     

    Item 3.   If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k)   [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     
     

     

     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
       

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

      (b) Percent of class:
         
       

    Avidity Partners Management LP: 0%

    Avidity Partners Management (GP) LLC: 0%

    Avidity Capital Partners Fund (GP) LP: 0%

    Avidity Capital Partners (GP) LLC: 0%

    Avidity Master Fund LP: 0%

    David Witzke: 0%

    Michael Gregory: 0%

     

      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

     

             
        (ii)   Shared power to vote or to direct the vote

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     
             
        (iii) Sole power to dispose or to direct the disposition of

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

     

             
        (iv)   Shared power to dispose or to direct the disposition of

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    Avidity Master Fund LP: 0

    David Witzke: 0

    Michael Gregory: 0

     

     

             

     

     
     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      N/A
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
       

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

     

    November 14, 2024

      (Date)
       
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

      By: /s/ David Witzke
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))
       
     

    Michael Gregory

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

      By: /s/Michael Gregory
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    Exhibit 1

    JOINT FILING AGREEMENT

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the Voting Common Stock, par value $0.0001 per share of Jasper Therapeutics, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing

     The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

    IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of November 14, 2024.

           
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

     

     

    /s/ David Witzke

     
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))
         
      Michael Gregory
      Avidity Partners Management LP
      Avidity Partners Management (GP) LLC
      Avidity Capital Partners Fund (GP) LP
     

    Avidity Capital Partners (GP) LLC

    Avidity Master Fund LP

         
      By:  /s/ Michael Gregory  
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP))

     

     

     

     

    Get the next $JSPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JSPR

    DatePrice TargetRatingAnalyst
    2/13/2025$38.00Buy
    UBS
    12/6/2024$63.00Outperform
    BMO Capital Markets
    9/9/2024$70.00Mkt Outperform
    JMP Securities
    7/8/2024$90.00Buy
    BTIG Research
    6/27/2024$86.00Buy
    Stifel
    5/6/2024$65.00Buy
    H.C. Wainwright
    4/3/2024$65.00Outperform
    Evercore ISI
    3/28/2024$70.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $JSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Mahal Jeetinder Singh

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:31:26 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President, CEO and Director Martell Ron

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:30:52 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Cross Herb

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/18/25 5:30:21 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

      REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B

      6/19/24 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

      REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re

      11/1/23 8:00:00 AM ET
      $DERM
      $JSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Jasper Therapeutics Strengthens Management Team with Key Appointments

      Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations

      8/2/23 8:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Jasper Therapeutics Inc.

      DEFA14A - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/19/25 8:02:13 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Jasper Therapeutics Inc.

      DEF 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/19/25 8:00:17 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

      5/12/25 4:05:08 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Jasper Therapeutics with a new price target

      UBS initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $38.00

      2/13/25 8:09:46 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Jasper Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $63.00

      12/6/24 7:52:11 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Jasper Therapeutics with a new price target

      JMP Securities initiated coverage of Jasper Therapeutics with a rating of Mkt Outperform and set a new price target of $70.00

      9/9/24 7:39:14 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Carlyle Group Inc. bought $2,460,500 worth of Voting Common Stock (190,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/12/24 6:23:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Velan Capital Investment Management Lp bought $4,532,500 worth of shares (350,000 units at $12.95) (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      2/9/24 8:40:05 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiggans Thomas G bought $6,486 worth of Voting Common Stock (10,000 units at $0.65), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

      11/30/23 4:05:16 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/14/24 6:01:49 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/14/24 3:32:57 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

      SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

      11/4/24 12:05:53 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jasper Therapeutics to Present at Upcoming Investor Conferences

      REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate in the following investor conferences: RBC Capital Markets 2025 Global Healthcare Conference Conference Dates: May 20-21, 2025Presentation Date/Time: Wednesday, May 21, 2025; 11:00 a.m. EDTPresentation Format: Fireside Chat Jefferies 2025 Global Healthcare ConferenceConference Dates: June 3-5,

      5/14/25 4:30:00 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

      REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The BEACON update, based on a data-cut date of January 31, 2025, features approximately one month of additio

      3/1/25 12:45:13 PM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

      REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced a late-breaking oral presentation of briquilimab data from the Phase 1b/2a BEACON in CSU study at the 2025 AAD Annual Meeting, being held March 7 - 11, 2025, in Orlando, FL. The presentation will consist of data from patients included in the Company's January 8th, 2025, disclosure of preliminary data from the BEACON study.

      2/28/25 8:00:59 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $JSPR
    Financials

    Live finance-specific insights

    See more
    • Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

      Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points 100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels Data supports commencement of CSU registrational program expected to commence second half of 2025 Company t

      1/8/25 7:00:37 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

      14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic induci

      10/14/24 7:00:00 AM ET
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care